LGR5 Overview
Molecule Name
Leucine-rich repeat-containing G-protein coupled receptor 5
Synonyms
LGR5, GPR49, GPR67, G-protein coupled receptor 49, G-protein coupled receptor 67, G-protein coupled receptor HG38, Leucine-rich repeat-containing G-protein coupled receptor 5
Drug Development Progress
Drugs in Clinical Trials2
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
FEX，G Protein-Coupled Receptor 49，GRP49，HG38，G-protein coupled receptor HG38，GPR49，GPR67，G-protein coupled receptor 49，Leucine-rich repeat-containing G-protein coupled receptor 5，LGR5，Leucine Rich Repeat Containing G Protein-Coupled Receptor 5，G-Protein Coupled Receptor 67，Orphan G Protein-Coupled Receptor HG38
Background
LGR5 (also known as GPR49) is a seven-transmembrane protein of the class A Rhodopsin-like family of GPCRs. LGR5 and LGR4 bind the R-spondins with high affinity and mediate the potentiation of Wnt/β-catenin signaling by enhancing Wnt-induced LRP6 phosphorylation. The LGR5/RSPO complex could promote Wnt signalling via the neutralization of two transmembrane E3 ligases, RNF43 and ZNRF3.
LGR5 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Petosemtamab | MCLA-158 | Phase 2 Clinical | Merus Nv | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| CNA-3103 | CNA-3103 | Phase 2 Clinical | Carina Biotech Pty Ltd | Colorectal Neoplasms | Details |